GLPwatch
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
NCT06737042 · Not yet recruiting
Last updated 2026-05-28This clinical trial is testing the safety and effects of the experimental drug GZR18, given every two weeks, compared to tirzepatide and a placebo in adults who are obese or overweight.
Status Not yet recruiting Approved but enrollment has not started.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 285 people Planned (estimated).
Who can join Ages 18–75 · all sexes
Timeline Started 2025-02 · est. completion 2026-06
Where 20 sites · United States
What this study is testing ClinicalTrials.gov NCT06737042 ↗
Description as written by the study sponsor.
This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).
Treatments tested
- GZR18 Drug
GLP-1
- Tirzepatide Drug
Active Comparator
| Main thing measured | Primary Objective |
|---|---|
| Sponsor | Gan and Lee Pharmaceuticals, USA |
| Conditions studied | Obesity and Overweight |
| GLP-1 drugs | tirzepatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06737042 ↗